TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03103087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Study: NCT01576354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged-release Fampridine
Description: 10mg tablet twice a day (every 12 hours), orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
Study: NCT02105987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC FDC
Description: Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
Study: NCT03326700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernia Repair
Description: Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernia Repair
Description: Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
Study: NCT00953576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Study: NCT01949090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
Study: NCT00122408

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ergyphilus
Description: 5 pills a day of Ergyphilus or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ergyphilus
Description: 5 pills a day of Ergyphilus or placebo
Study: NCT03760523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
Study: NCT03988764

Intervention type: OTHER
Intervention: None AHT
Description: No further intervention planned for either group as part of the current study.

Intervention type: OTHER
Intervention: None AHT
Description: No further intervention planned for either group as part of the current study.
Study: NCT01574352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small intervention
Description: The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention camp
Description: The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
Study: NCT04642729

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fresh Corneal Lenticule Implantation using Relex-Smile Surgery
Description: Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fresh Corneal Lenticule Implantation using Relex-Smile Surgery
Description: Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
Study: NCT01532765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy and epiretinal membrane peel
Description: 23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy and epiretinal membrane peel
Description: 23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
Study: NCT00953576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Study: NCT03957291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
Study: NCT01532765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy and epiretinal membrane peel
Description: 23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy and epiretinal membrane peel
Description: 23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peel assisted by ICG
Description: Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peel assisted by ICG
Description: Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CE-IOL
Description: Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CE-IOL
Description: Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
Study: NCT04912921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: palmitoylethanolamide
Description: 4 tablets taken daily (2 in the am and 2 in the pm)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets taken daily (2 in am and 2 in pm)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 500 mg HydroCurc® twice a day
Study: NCT02116309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Indomethacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Indomethacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Study: NCT03773159

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 4 citrated/PPACK tubes and 1 EDTA tube maximum

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: 4 citrated/PPACK tubes and 1 EDTA tube maximum
Study: NCT03076827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: Total hip replacement starts in the morning in group A and starts in the afternoon in group P.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: Total hip replacement starts in the morning in group A and starts in the afternoon in group P.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-arthroplasty
Description: Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-arthroplasty
Description: Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
Study: NCT02568176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral dose of midazolam 6 mg Day 1 and Day 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Intranasal esketamine will be self-administered 5 times during 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Intranasal esketamine will be self-administered 5 times during 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Single oral dose of bupropion 150 mg on Day 1 and 19.
Study: NCT01955824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% lignocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lignocaine
Study: NCT01314508

Intervention type: DRUG
Group type: OTHER
Intervention: Increlex
Description: Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
Study: NCT01252914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent Supra Stent
Description: Implantation of one iStent Supra Stent through a small temporal clear corneal incision
Study: NCT02293720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier
Description: The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
Study: NCT04146545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Rx-Dementia CRxD Caregiver Resources
Description: A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
Study: NCT00636857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative fluid management based on Lean Body Mass
Description: Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
Study: NCT03526848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117
Study: NCT04912921

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (microcrystalline cellulose)
Description: 2 tablets taken daily
Study: NCT03090256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ PanOptix™ IOL
Description: Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
Study: NCT01176552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF, IFN alpha and IL-2
Description: Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
Study: NCT02637843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slender Sheath
Description: Comparing outcomes for two different sheaths used during radial CAG/PCI
Study: NCT02553746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Detection of the puncture site by ultrasound scan of the lumbar spine.
Description: Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Detection of the puncture site by identification of the landmarks.
Description: Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
Study: NCT01863472

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartLight(TM) Laser Balloon
Description: With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: irrigated radiofrequency current ablation
Description: The irrigated radiofrequency current ablation is used for pulmonary vein isolation
Study: NCT03612037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid
Description: 600 mg/day oral dose of alpha lipoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: 600mg/day oral dose of placebo cellulose
Study: NCT03346122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64991524 Dose Level 1
Description: Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
Study: NCT03526848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 3BNC117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption
Description: Analytical treatment interruption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption
Description: Analytical treatment interruption
Study: NCT04114461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-TOF tab. 5mg
Description: HL-TOF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeljanz tab. 5mg
Description: Xeljanz
Study: NCT04116307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polymethylsiloxane

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Study: NCT04311814

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Maximum urethral closure pressure during Valsalva (v-MUCP)
Description: v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
Study: NCT00145795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra + Current Dual NRTI Backbone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current Regimen
Study: NCT00766129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taxus stent implantation
Description: Patients will be treated with implantation of Taxus stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luc-Chopin stent
Description: Patients will be treated will implantation of Luc-Chopin stent
Study: NCT02779049

Intervention type: OTHER
Intervention: Blood examination
Description: blood sampling
Study: NCT03871231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unpinning Termination Therapy
Description: The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
Study: NCT02789241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
Study: NCT02789241

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
Study: NCT01955291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reinforced Feedback in Virtual Environment (RFVE)
Description: The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Neuromotor Rehabilitation
Description: The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
Study: NCT02787655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + Cognitive Training Group
Description: stationary bicycling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training Only
Description: 20 minutes of cognitive training using Mindfit program
Study: NCT04037579

Intervention type: OTHER
Intervention: Survey
Description: Non-randomised survey
Study: NCT02779049

Intervention type: OTHER
Intervention: Blood examination
Description: blood sampling

Intervention type: OTHER
Intervention: Blood examination
Description: blood sampling
Study: NCT04288414

Intervention type: DIAGNOSTIC_TEST
Intervention: functional near-infrared spectroscopy
Description: Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
Study: NCT05096741

Intervention type: DEVICE
Intervention: OCS Liver
Description: Transplanted with a OCS preserved liver
Study: NCT06431126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature and animal-assisted activities
Description: Supervised activities on a farm, 2 half day/week for 12 weeks